N (%) | Overall Population | Symptomatic AL (SAL) | Asymptomatic AL (AAL) | Without AL (WAL) | P |
---|---|---|---|---|---|
200 (100) | 29 (14.5) | 10 (5.0) | 161 (80.5) | ||
T stage, n (%) | |||||
T0 | 28 (14.0) | 2 (6.9) | 2 (20.0) | 24 (14.9) | 0.460 |
T1 | 30 (15.0) | 5 (17.2) | 0 | 25 (15.5) | |
T2 | 57 (28.5) | 7 (24.1) | 5 (50.0) | 45 (27.9) | |
T3 | 78 (39.0) | 14 (48.3) | 2 (20.0) | 62 (38.5) | |
T4 | 7 (3.5) | 1 (2.9) | 1 (10.0) | 5 (3.1) | |
N stage, n (%) | |||||
N+ | 48 (24.0) | 5 (17.2) | 2 (20.0) | 41 (25.5) | 0.594 |
N0 | 152 (76.0) | 24 (82.8) | 8 (80.0) | 120 (74.5) | |
Pathological response, n (%) | |||||
Absent | 59 (28.5) | 11 (38.0) | 1 (10.0) | 47 (29.2) | |
Partial | 113 (56.5) | 17 (58.6) | 7 (70.0) | 89 (55.3) | 0.479 |
Complete | 28 (14.0) | 1 (3.4) | 2 (20.0) | 25 (15.5) | |
Lymph nodes, median ± IQR | 18.0 (13.0–25.5) | 18.0 (12.5–23.5) | 18.5 (15.0–25.0) | 17.5 (13.0–26.0) | 0.593 |
Tumor diameter (mm), median ± IQR | 25.5 (20.0–35.5) | 27.5 (20.0–35.0) | 30.0 (22.5–37.5) | 25.0 (18.0–35.0) | 0.971 |
Resection margins, n (%) | |||||
Incomplete (R+) | 9 (4.5) | 3 (10.3) | 1 (10.0) | 5 (3.1) | |
Complete (R0) | 191 (95.5) | 26 (89.7) | 9 (90.0) | 156 (96.9) | 0.151 |